-
1
-
-
84992382894
-
Eligibility for the shorter multidrug-resistant tuberculosis regimen: Ambiguities in the World Health Organization recommendations [letter
-
Varaine F, Guglielmetti L, Huerga H, Bonnet M, Kiria N, Sitienei JK, Rich M, Mitnick CD. Eligibility for the shorter multidrug-resistant tuberculosis regimen: ambiguities in the World Health Organization recommendations [letter]. Am J Respir Crit Care Med 2016;194:1028–1029.
-
(2016)
Am J Respir Crit Care Med
, vol.194
, pp. 1028-1029
-
-
Varaine, F.1
Guglielmetti, L.2
Huerga, H.3
Bonnet, M.4
Kiria, N.5
Sitienei, J.K.6
Rich, M.7
Mitnick, C.D.8
-
2
-
-
84992323965
-
Limited benefit of the new shorter multidrug-resistant tuberculosis regimen in Europe
-
letter
-
Lange C, Duarte R, Fréchet-Jachym M, Guenther G, Guglielmetti L, Olaru ID, Oliveira O, Rumetshofer R, Veziris N, van Leth F; European MDR-TB Database Collaboration. Limited benefit of the new shorter multidrug-resistant tuberculosis regimen in Europe [letter]. Am J Respir Crit Care Med 2016;194:1029–1031.
-
(2016)
Am J Respir Crit Care Med
, vol.194
, pp. 1029-1031
-
-
Lange, C.1
Duarte, R.2
Fréchet-Jachym, M.3
Guenther, G.4
Guglielmetti, L.5
Olaru, I.D.6
Oliveira, O.7
Rumetshofer, R.8
Veziris, N.9
Van Leth, F.10
-
4
-
-
0345306174
-
EthA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates
-
Morlock GP, Metchock B, Sikes D, Crawford JT, Cooksey RC. ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2003;47:3799–3805.
-
(2003)
Antimicrob Agents Chemother
, vol.47
, pp. 3799-3805
-
-
Morlock, G.P.1
Metchock, B.2
Sikes, D.3
Crawford, J.T.4
Cooksey, R.C.5
-
5
-
-
84954510585
-
Resistance to isoniazid and ethionamide in Mycobacterium tuberculosis: Genes, mutations, and causalities
-
MGM2–MGM0014-2013
-
Vilchèze C, Jacobs WR Jr. Resistance to isoniazid and ethionamide in Mycobacterium tuberculosis: genes, mutations, and causalities. Microbiol Spectr 2014;2:MGM2–MGM0014-2013.
-
(2014)
Microbiol Spectr
, vol.2
-
-
Vilchèze, C.1
Jacobs, W.R.2
-
6
-
-
38949175355
-
A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis
-
Katiyar SK, Bihari S, Prakash S, Mamtani M, Kulkarni H. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2008;12:139–145.
-
(2008)
Int J Tuberc Lung Dis
, vol.12
, pp. 139-145
-
-
Katiyar, S.K.1
Bihari, S.2
Prakash, S.3
Mamtani, M.4
Kulkarni, H.5
-
7
-
-
84947422751
-
High prevalence of inha promoter mutations among patients with drug-resistant tuberculosis in KwaZulu-Natal, South Africa
-
Niehaus AJ, Mlisana K, Gandhi NR, Mathema B, Brust JC. High prevalence of inha promoter mutations among patients with drug-resistant tuberculosis in KwaZulu-Natal, South Africa. Plos One 2015; 10:e0135003.
-
(2015)
Plos One
, vol.10
-
-
Niehaus, A.J.1
Mlisana, K.2
Gandhi, N.R.3
Mathema, B.4
Brust, J.C.5
-
8
-
-
84987710871
-
-
World Health Organization. Annexes 4, 5, and 6. Geneva, Switzerland: WHO Document Production Services
-
World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis. 2016 update. Annexes 4, 5, and 6. Geneva, Switzerland: WHO Document Production Services; 2016.
-
(2016)
WHO Treatment Guidelines for Drug-Resistant Tuberculosis. 2016 Update.
-
-
-
9
-
-
84907033159
-
High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: No relapses
-
Piubello A, Harouna SH, Souleymane MB, Boukary I, Morou S, Daouda M, Hanki Y, Van Deun A. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis 2014;18:1188–1194.
-
(2014)
Int J Tuberc Lung Dis
, vol.18
, pp. 1188-1194
-
-
Piubello, A.1
Harouna, S.H.2
Souleymane, M.B.3
Boukary, I.4
Morou, S.5
Daouda, M.6
Hanki, Y.7
Van Deun, A.8
|